Clinical Trial Update: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer [Phase 3]

View source ↗

Summary

This update reports results from a Phase 3 trial of olaparib as adjuvant treatment in germline BRCA-mutated high-risk HER2-negative primary breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-12-08